Evidence map›Paper›PMID 41023832›Full record

ArticleBMC medical research methodology2025

Modeling strategies for a flexible estimation of the crude cumulative incidence in the context of long follow-ups: model choice and predictive ability evaluation.

Giacomo Biganzoli, Giuseppe Marano, Patrizia Boracchi

Abstract read
In one paragraph

Article in BMC medical research methodology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Giacomo BiganzoliUnit of Medical Statistics and Bioinformatics, Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Milan, Italy. giacomo.biganzoli@unimi.it.
Giuseppe MaranoUnit of Medical Statistics and Bioinformatics, Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Milan, Italy.
Patrizia BoracchiUnit of Medical Statistics and Bioinformatics, Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvancements in treatments for chronic diseases, such as breast cancer, have expanded our ability to observe patient outcomes beyond disease-related mortality, including events like distant recurrences. However, competing events can complicate the interpretation of primary outcomes, making the crude cumulative incidence function the most reliable measure for accurate follow-up analysis. Long-term studies require flexible modeling to accommodate intricate, time-dependent effects and interactions among covariates. Traditional models, such as the proportional sub-distribution hazards model, often insufficient to address these complexities. Although more adaptable methods have been proposed, there is still a need to systematically assess model complexity, particularly for exploratory purposes. This article presents a statistical learning workflow designed to evaluate model complexity in crude cumulative incidence and introduces a time-dependent metric for predictive accuracy. This framework provides researchers with an enhanced toolkit for robustly addressing the complexities of long-term outcome modeling and deriving interpretable prognostic algorithms.

methodsWe demonstrate our approach using data on time-to-distant breast cancer recurrences from the Milan 1 and Milan 3 trials, which have extensive follow-up periods. Two flexible modeling frameworks-pseudo-observations and sub-distribution hazard models-are employed, enhanced with spline functions to capture baseline hazard and risk. Our proposed workflow integrates graphical representations of Aalen-Johansen estimates for crude cumulative incidence, enabling researchers to visually hypothesize and adjust model complexity to match the studied phenomenon. Information criteria guide model selection to approximate the underlying data structure. Using bootstrapped data perturbations and time-dependent predictive accuracy measures, adjusted with Harrell's optimism correction, we identify the optimal model structure, balancing explainability, predictivity, and generalizability.

resultsOur findings highlight the importance of data perturbation and validation through optimism-corrected predictive measures following the original data analysis. The initial model structure may differ from the most robust model identified through iterative perturbation. The ideal model has high robustness (most frequently selected in perturbations), strong explainability, and predictive capacity. When perturbation results are inconsistent, evaluating various time-dependent predictive measures offers additional insights, particularly regarding the trade-off between model complexity and predictive gains. In cases where predictive improvement is minimal, simpler and more explainable model structures are preferable.

conclusionsThe proposed statistical learning workflow, informed by domain expertise, allows for incorporating clinically relevant complexities in the prognostic modeling of distant recurrences in breast cancer. Our results suggest that, in many cases, a nuanced and flexible model structure may better serve future predictions than simpler models. This approach underscores the value of balancing model simplicity and complexity to achieve meaningful, clinically useful insights.

Indexed as

Breast NeoplasmsModels, StatisticalNeoplasm Recurrence, LocalAlgorithmsFemaleFollow-Up StudiesHumansIncidencePrognosisProportional Hazards ModelsCompeting risksFlexible modelingGeneralized linear modelspseudo-observationsSurvival analysis

Identifiers

PMID41023832
PMCPMC12481988

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.